Group 1 pulmonary hypertension (or pulmonary arterial hypertension) is a rare, highly complex, and progressive disorder that is incurable and ultimately can lead to premature death. PAH causes ...

Although some cases of PAH have known causes, such as genetic factors, many cases have no identifiable underlying cause and are designated as idiopathic. Early diagnosis and treatment are critical for ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Merck recently rolled out its latest campaign focusing on pulmonary arterial hypertension (PAH), a serious and progressive disease that can cause heart failure and lower life expectancy. PAH is a rare ...

PAH has been shown to be related to adipocyte dysfunction, obesity, and estrogens. CYP1B1 is highly expressed in adipose tissue and overexpressed in pulmonary artery smooth muscle cells in patients ...

Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...

Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat pulmonary arterial hypertension (PAH), Merck has kicked off an educational campaign around the rare disease. The “Outnumber ...